

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mangel et al.  
Intl. Serial No.: To Be Assigned Group Art Unit: To Be Assigned  
Intl. File Date: Concurrently Herewith Examiner: To Be Assigned  
For: Use of COX-2 Inhibitors As Gastroprokinetics

Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☐ Copies of the references are enclosed:  
☒ Copies of the references were submitted in parent application Serial No. 10/182,080 (37 CFR 1.98(d))  
☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
  - (2) a notice of allowance under § 1.311, whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan

Registration No. 38,181

Date:

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222

Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET NO.</b> <b>PG3731US2</b>		<b>SERIAL NO.(Intern'l)</b> <b>To Be Assigned</b>	
				<b>APPLICANT: Mangel et al.</b>			
				<b>FILING (Intern'l) Date:</b> <b>Concurrently Herewith</b>		<b>GROUP</b>	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	US2001/0041726	11-15-01	Bandarage et al.			
Continue on page _____							
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	BA	EP 0 812 519 A	Dec. 17, 1997	EPO			
	BB	WO 00 48583 A	Aug. 24, 2000	PCT			
	BC	GB 2 325 161 A	Nov. 18, 1998	GB			
Continue on page _____							
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
	CA	Josephs, MD; et al. "Products of Cyclooxygenase-2 Catalysis Regulate Postoperative Bowel Motility." Journal of Surgical Research, Vol. 86, No. 1, 1999, p. 52.					
	CB	Hayakawa, T; et al. "Effects of DAI-Kenchu-TO on Intestinal Obstruction Following Laparotomy." Journal of Smooth Muscle Research, Vol. 35, No. 2, 1999, pages 47-54.					
	CF	Morgan, G: "Beneficial Effect of NSAIDS in the Gastrointestinal Tract." European Journal of Gastroenterology and Hepatology, Vol. 11, No. 4, 1999, pages 393-400.					
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							